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ABSTRACT 
Advances in prostate cancer biology and diagnostics are dependent upon high fidelity 
integration of clinical, histomorphologic, and molecular phenotypic findings. In this study we 
compared fresh frozen (FF), formalin-fixed paraffin-embedded (FFPE), and PAXgene-fixed 
paraffin-embedded (PFPE) tissue preparation methods in radical prostatectomy prostate 
tissue from 36 patients and did a preliminary test of feasibility of using PFPE tissue in routine 
prostate surgical pathology diagnostic assessment. In addition to comparing histology, 
immunohistochemistry, and general measures of DNA and RNA integrity in each fixation 
method, we performed functional tests of DNA and RNA quality including targeted Miseq 
RNA and DNA sequencing, and implemented methods to relate DNA and RNA yield and 
quality to quantified DNA and RNA picogram nuclear content in each tissue volume studied. 
Our results suggest that it is feasible to use PFPE tissue for routine robot-assisted 
laparoscopic prostatectomy (RALP) surgical pathology diagnostics and 
immunohistochemistry, with the benefit of significantly improved DNA and RNA quality and 
RNA picogram yield per nucleus as compared to FFPE tissue. For FF, FFPE, and PFPE 
tissues respectively, average Genomic Quality Numbers (GQNs) were 7.9, 3.2, and 6.2, 
average RNA Quality Number (RQNs) were 8.7, 2.6, and 6.3, average DNA picogram yields 
per nucleus were 0.41, 0.69, and 0.78, and average RNA picogram yields per nucleus were 
1.40, 0.94, and 2.24. These findings suggest that where DNA and/or RNA analysis of tissue 
is required, and when tissue size is small, PFPE may provide important advantages over 
FFPE. The results also suggest several interesting nuances including potential avenues to 
improve RNA quality in FFPE tissues, and confirm recent suggestions that some DNA 
sequence artifacts associated with FFPE can be avoided.  
 
INTRODUCTION 
Advances in prostate cancer biology and diagnostics are dependent upon high fidelity 
integration of clinical, histomorphologic, and molecular phenotypic findings. While frozen 
tissue can provide excellent molecular preservation, it is not suitable for routine surgical 
pathology as histologic detail is often insufficient, and frozen tissue handling is too 
cumbersome for routine analysis of entire prostates. Formalin-fixed, paraffin-embedded 
(FFPE) tissue processing, the current standard in surgical pathology, provides good 
histomorphology, but RNA and DNA isolated from FFPE tissue is significantly reduced both 
in overall yield and quality relative to frozen tissue.  
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PAXgene™ fixative (Preanalytix GmbH, Switzerland) is a non-crosslinking fixation reagent 
containing methanol and acetic acid (PAXgene Tissue Fix Container Circular). Studies have 
found PAXgene-fixed, paraffin-embedded (PFPE) tissue histology generally comparable to 
FFPE tissue in various tissue types1–4. However, depending on the epitope studied, 
immunohistochemistry (IHC) in PFPE tissue sections may require modification of IHC 
protocols originally optimized for FFPE3,5. Published comparative analysis of FFPE and 
PFPE prostate tissue is limited to a total of 13 cases from autopsy or surgery1,3,6. Prostate 
PFPE tissue histology has been reported to contain artifacts such as pyknosis of nuclei, cell 
shrinkage and lower contrast of the prostate epithelium compared to FFPE tissue in H&E 
stained specimens obtained at surgery6. Gillard et al reported RIN scores <2 in PFPE and 
FFPE material from apparently both autopsy and prostatectomy specimens, but no 
preanalytical tissue handling data was provided1. No study yet reported has directly compared 
fresh frozen (FF), FFPE, and PFPE molecular integrity and assessed general histologic 
quality in a blinded fashion in a substantial number of cases. 
 
In this study we compared FF, FFPE, and PFPE tissue preservation methods for prostate 
tissue and did a preliminary test of feasibility of using PFPE tissue in routine prostate surgical 
pathology diagnostic assessment. We attempted to optimize every step of sample handling 
from robot-assisted laparoscopic prostatectomy surgery through processing, embedding, and 
storage of tissue blocks, with the intent of obtaining the best combination of histology and 
macromolecule quality for all three types of tissue studied (FF, FFPE, and PFPE). In addition 
to comparing histology, IHC, and general measures of DNA and RNA integrity in each 
fixation method, we performed functional tests of DNA and RNA quality, and implemented 
methods to relate DNA and RNA yield and quality to quantified nuclear content in each 
tissue volume studied.   
MATERIALS AND METHODS 
 
Study Design 
We compared FF, FFPE and PFPE tissue quality in two phases (Fig. 1). In the first phase 
comprising tissue samples from 20 robot-assisted laparoscopic prostatectomy (RALP) cases 
herein referred to as the 4-core study, we compared FF, FFPE and PFPE results using two 
different tissue processors for PAXgene-fixed prostate tissue; a Shandon Citadel 2000 
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research histoprocessor and a Pathos Delta processor in use in surgical pathology (Fig. 1A). 
The RNA quality results in the 4-core study were less than desired (Supplemental Figure 1), 
compelling us to continue the study in a second phase using adjusted methods. The second 
phase (3-core study) comprised an additional 16 RALP cases where PAXgene fixed material 
was processed using a Leica TP1020 processor dedicated solely to PAXgene-fixed samples, 
and included use of reduced melting point paraffin (Fig. 1B).  Methods and results for both 
phases of the study are reported here and summarized in Supplemental Table 1. 
Tissue Collection and Sampling  
Prostate tissue from robot-assisted laparoscopic prostatectomy (RALP) was used for the 
study. Consecutive cases from all surgeons performing RALP where tissue accrual 
coordinators (G.H., K.K., T.T.) were available were included in the study. Tissue used for the 
study remained available for routine diagnostic use. 
RALP specimens were delivered from the operating room to surgical pathology (Fimlab, 
Laboratories, Tampere, Finland) by pneumatic tube in internally sterile specimen bags. Upon 
arrival, the prostate was immediately weighed in its bag and the prostate core temperature 
was measured with a sterile digital meat thermometer probe inserted to the midpoint of the 
prostatic urethra. Approximately 30 mL of Sterile 4°C saline solution was poured into the 
plastic bag containing the tissue to enhance heat transfer, the bag was covered with ice, and 
the prostate was cooled over 7-10 minutes to 15°C or below. The prostate was then inked for 
routine surgical pathology margin analysis (Supplemental Methods) and a 6 mm thick 
transverse tissue slice was cut midway between apex and base with a sterile custom-made 
tissue slicer. This tissue slice was placed on a sterile dissection plate with its apical side 
facing up. In the four-core study, four tissue core punches (A, B, C, and D) were taken with a 
sterile 8 mm diameter tissue biopsy punch (33-37-10, Miltex) clockwise along the anterior 
side of the prostate, each 3-4 mm away from the inked outer surface of the prostate as shown 
in Figure 1A to avoid risk of interfering with microscopic assessment of capsular margins. In 
the three-core study, three tissue core punches (A, B and C) were taken with a sterile 6 mm 
diameter tissue biopsy punch (33-36-10, Miltex), each 3-4 mm away from the inked outer 
surface of the posterolateral surface of the prostate as shown in Fig. 1B. In the 3-core study, 
the cores were taken from the left or right posterolateral position depending on the side most 
likely to contain cancer based on pre-operative biopsy results and pathologist’s gross 
assessment of the tissue after slicing. Before removing the cores for fixation, the upward 
facing apical sides of each core were blue-inked to allow for correct orientation on 
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embedding. Core A was placed directly onto a cryomold and refrigerated OCT (Optimal 
Cutting Temperature; Sakura Finetek Europe B.V.) compound was placed around it. Core A 
was then snap frozen in -90°C isopentane for 15 seconds before storing it in -80ºC. Core B 
was placed in a labelled nylon mesh tissue bag (6774017, Thermo Scientific), fixed in 10% 
buffered Formalin (122256, Reagena International Oy Ltd) at least 24 hours, and processed in 
the next routine surgical pathology tissue processing run. Core C and D were placed in a 
labelled nylon mesh bag and fixed in 50 ml PAXgene fixative (Qiagen/PreAnalytix Cat No. 
765312) for 4 hours at room temperature with gentle rocking (oscillating approximately once 
per minute). After fixation the C and D cores were transferred to 150 ml PAXgene Stabilizer 
diluted according to manufacturer instructions (Qiagen/PreAnalytix Cat. No. 765512) and 
stored at 4ºC until processing. After core sampling, the transverse prostate donor tissue slice 
was put into a Supa Mega Slim white cassette (CellPath, EAN 0102-02A) to reduce warping 
of the tissue during fixation and was placed in 10% buffered formalin.  
Tissue Processing and Embedding 
In both the 3-core and 4-core studies, the formalin-fixed B cores in nylon mesh bags were 
processed together with the whole mount prostate slice from which the cores were taken in a 
Pathos Delta processor as part of routine surgical pathology tissue processing at Fimlab 
(Supplemental Table 2). B cores were embedded in regular tissue cassettes in Histowax 
paraffin (melting point 56C-58C, Histolab), with the inked apical side as the initial cutting 
surface. In the 4-core study, the C and D cores were stored in Stabilizer solution at 4ºC 
between 16 hours to 20 days before processing, which was completed in three batches. The C 
cores were processed using newly replenished processing liquids in a fully cleaned Shandon 
Citadel 2000 research histoprocessor, and D cores were processed using replenished liquids 
in a fully cleaned Pathos Delta processor. C and D cores were embedded in Histowax in 
regular cassettes immediately upon processor run completion. In the 3-core study, the C cores 
were stored from 3 to 14 days in Stabilizer at 4ºC and were all processed in labeled nylon-
mesh bags in one batch in a Leica TP1020 processor using Paraplast Xtra (melting point 50C-
54C, P3808 Sigma-Aldrich) as embedding medium. Immediately upon processor run 
completion, C core tissues were removed from the wax chamber and embedded in Paraplast 
Xtra paraffin in regular cassettes. Detailed processing steps for the C and D cores in the two 
phases of the study are contained in Supplemental Tables 3-5. All study B, C, and D-core 
tissue blocks were stored at 4ºC when not being sectioned.   
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Tracking of Blocks, Slides, Tissue Reagents, Methods, and Results 
All study blocks, slides, tissue reagents, images, methods, and results are tracked using 
unique identifiers and barcodes in a laboratory Integrated Life Science Research (ILSR) 
database. 
Core Sectioning for H&E, IHC, and DNA/RNA Isolation 
Consecutive tissue sections were cut from each core block for H&E (Hematoxylin and Eosin) 
staining, IHC and DNA/RNA extraction. For the paraffin-embedded B, C and D cores a 4 μm 
thick section was first cut with a microtome for H&E, followed by six 4 μm sections to be 
used for IHC staining. The slides were baked for 2 hours at 62.5ºC. After this, excess paraffin 
was trimmed away from the face of each block and 12 ten μm sections, comprising a tissue 
volume of 6.0 mm3, or 22 ten μm sections, comprising a tissue volume of 6.2 mm3, were cut 
from the 4-core study and 3-core study blocks, respectively. The tissue sections were placed 
into 1.5.ml Eppendorf tubes for DNA and RNA extraction (Fig. 2). For the A (frozen) cores, 
a 6 μm section was first cut with a cryotome for H&E staining, then excess OCT compound 
was removed before cutting 12 (4-core study) or 22 (3-core study) ten μm sections for nucleic 
acid extraction (Fig. 2).   
Hematoxylin and Eosin Staining 
In the 4-core study, four micron sections from B, C and D cores were stained by hand with 
the same H&E protocol optimized to give reasonably good quality staining in both FFPE and 
PFPE tissues (Supplemental Table 6). H&E staining of A core sections was done with a 
standard protocol for frozen sections (Supplemental Table 7). In the 3-core study, four 
micron sections from B cores were H&E stained at Fimlab pathology laboratory with an 
automated staining machine using their standard H&E protocol (Supplemental Table 8). To 
match the eosin staining intensity of the B cores as closely as possible, the PAXgene-fixed C 
cores were stained by hand using a modified protocol with diluted eosin and shorter eosin 
exposure time (Supplemental Table 9). Eosin concentration and time in eosin was reduced 
from 100% to 50% and 1 minute to 5 seconds respectively for PAXgene sections as 
compared to sections from formalin-fixed cores. The H&E staining protocol for frozen 
sections from A cores were similarly optimized to match staining intensities of formalin and 
PAXgene fixed sections (Supplemental Table 10). 
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Immunohistochemistry 
Four micron sections from B, C and D cores for IHC were placed on either SuperFrost plus 
slides (PSA, ERG, Vimentin stains) or TOMO slides (Matsunami glass Ind., Ltd) (2IHC 
stain) using automated Bond III technology (PSA, ERG and Vimentin) or Ventana 
Benchmark GX technology (“2IHC” CK5/6, p63 and AMACR cocktail) (Fimlab) (detailed 
protocol in Supplemental Methods). The IHC sections were counterstained with hematoxylin. 
Overall immunohistochemistry results were compared for each trio of BCD IHC sections (4-
core study) or BC IHC sections (3-core study) by two pathologists (T.T. and G.S.B.). 
Whole Slide Imaging 
H&E and IHC whole slide images in the 4-core study were obtained at 40x magnification 
with an Olympus BX51, Olympus UplanSApo 40x objective and Surveyor Software, 
Objective Imaging Ltd., and in the 3-core study with a Hamamatsu Photonics Nano Zoomer 
XR C12000 automated scanner.  QC on whole slide images was done by visual inspection of 
the slides to make sure all images were in focus.  
Surgical Pathologist Web-Based Survey 
Five surgical pathologists (T.T., T.M., P.H., M.L., and P.K.) participated in a web-based 
survey including histologic images from study PFPE and FFPE tissue cores, from sections 
adjacent to those used for DNA and RNA isolation and analysis. Survey instructions and the 
specific questions used are contained in Supplemental Methods. For each of 14 FFPE and 19 
PFPE blocks from the 3-core and 4-core studies containing cancer, paired H&E and 2IHC 
(AMACR, p63 and CK 5/6) stained section zoomable whole slide images were presented in 
randomized order to the pathologists at a computer of their choice. Pathologists were blinded 
to the case number, core identity, and fixative for each pair of images presented. For each 
pair of images, the pathologist was required to make a best estimate of what fixative was used 
(PAXgene or Formalin) and was required to choose whether or not the quality appeared 
adequate for routine radical prostatectomy surgical pathology analysis.    
Nucleic Acid Extraction and Quality Assessment 
Genomic DNA and total RNA, including miRNA, was extracted from all cores. Different 
column based extraction kits from Qiagen (Hilden, Germany) were used to isolate nucleic 
acids from the different tissue preparations as recommended by the manufacturer. AllPrep 
DNA/RNA/miRNA Universal kit (Qiagen, cat no 80224) was used for simultaneous 
extraction of DNA and RNA from the fresh frozen A cores and the Allprep DNA/RNA FFPE 
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kit (Qiagen, cat no 80234) was used for the formalin-fixed B cores. For the PAXgene-fixed C 
and D cores DNA and RNA was extracted with the PAXgene Tissue Allprep 
DNA/RNA/miRNA method (Qiagen’s PX10 Supplemental protocol) where material from the 
PAXgene Tissue DNA Kit (Qiagen/PreAnalytix cat no 767134) and PAXgene Tissue 
miRNA Kit (Qiagen/PreAnalytix, cat no 766134) were used. The extractions were performed 
according to the manufacturer’s instructions apart from modification of the deparaffinization 
protocols (details in Supplemental Methods). In brief, deparaffinization of 3-core study B 
core sections and 4-core study B, C and D core sections was performed by incubating the 
samples for 20 min at 37ºC with 1400 µl heptane, and deparaffinization of 3-core study C 
core sections was performed by incubating the samples for 10 minutes at room temperature 
with 650 µl xylene. The cut sections were stored in -80ºC and extractions were performed 
within two weeks after cutting. 60 μl of DNA and 40 μl of RNA was isolated and the eluted 
samples were stored at -20ºC and -80ºC, respectively.  
 
DNA concentration was measured with the Qubit 2.0 Fluorometer (Invitrogen Life 
Technologies, Carlsbad, CA). Genomic DNA was run on a 0.6% agarose gel stained with 
0.5x SYBR Safe DNA dye (Invitrogen) at 80V for 70 minutes and DNA band size examined 
under UV-light. DNA quality and RNA concentration and quality was measured with 
Fragment Analyzer (FA) (Advanced Analytical Technologies, Ankeny, IA) using the DNF-
467 Genomic DNA 50kb Analysis kit and the DNF-489 Standard Sensitivity RNA Analysis 
kit. The results were analyzed with Fragment Analyzer PROsize 2.0 version 2.0.0.51 
software. PROsize determines a Genomic Quality Number (GQN) based on relative quantity 
of genomic DNA above a user-defined 10 kb size threshold. When analyzing RNA, PROsize 
determines the percentage of RNA over 200 nucleotides in size (DV200) and an RNA Quality 
Number (RQN) value based on the area and ratios of the 18S and 28S ribosomal RNA peaks. 
DV200 >70% is considered high quality and 30-50% low quality RNA for Illumina’s 
(Illumina, San Diego, CA) RNA Seq library preparation7. According to Advanced Analytical 
Technologies, Fragment Analyzer RQN number and Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA) RIN number measured in comparison RNA samples are 
highly correlated (R2= 0.9635)8.   
 
For the 3-core study samples, DNA quality of FF, FFPE and PFPE DNA was also analyzed 
with a qPCR (real time quantitative Polymerase Chain Reaction)-based FFPE QC kit 
(Illumina Kit WG-321-1001). This method compares the Ct (threshold cycle) of amplification 
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for control template and experimental DNA samples; a ΔCt value (Sample DNA Ct minus 
QC Template DNA Ct) of ≤ 2 is considered good quality DNA. Extracted DNA was diluted 
to 1 ng/µl and run in triplicate according to manufacturer’s instructions.  
Manual and Automated Nucleus Counts 
Nucleus counts were obtained from the H&E stained face section whole slide images of A, B 
and C cores in the 3-core study using an automated nucleus counting method. All 
hematoxylin stained nuclei were manually counted from one 550 µm x 550 µm image 
randomly selected from every A, B and C core whole slide image, resulting to a total of 
71239 manually annotated nuclei. Manual counting was done using the Cell Counter plugin 
in Image J software (v. 1.48, National Institutes of Health, Bethesda, MD), and coordinates 
with the position of each manually counted nucleus was saved for optimization of the 
automated counting method. Nucleus segmentation was done for color adjusted images. We 
used a histogram matching method for color adjustment, using a composite image histogram 
as a reference for the matching of red, green and blue channels. Nucleus segmentation was 
done in two passes. First, a smoothened pixelwise ratio image between red and blue channels 
was binarized using an experimentally defined threshold value. Second, any undersegmented 
connected components (larger than twice of the area of a typical nucleus) were thresholded 
using another threshold and the remaining large objects were further split using marker 
controlled watershed segmentation. Detected areas smaller than 4 µm2 were cleaned from the 
results by applying area constraints. Finally, small bleed-through areas of blue ink used for 
external marking of correct orientation of the core were excluded by applying hue and 
saturation based thresholding as criteria. All parameters were tuned by using the manually 
counted cells as a validation set. The accuracy of segmentation was determined for the 71239 
annotated cells as an F1-score, weighting both false positive and false negative errors equally. 
The average F1-score among the annotated images, defined as 2*precision*recall/(precision 
+ recall)9 was 0.78. Average precision (TP/(TP+ FP) was 0.85 and recall (TP/TP+FN) 0.73, 
where TP, FP are true and false positive detections, respectively, and FN denotes false 
negatives.  
Per-Nucleus DNA and RNA Yield Estimation 
Total nuclear count from all sections used for nucleic acid isolation was estimated based on 
the number of nuclei present in the adjacent H&E section from each core (see Fig 2), the 
thickness of tissue taken for DNA/RNA extraction and the median nuclear diameter. Median 
diameter was calculated for all segmented nuclei in A, B and C core images by assuming 
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spheroid shape with diameters estimated from segmented nuclei as axes of ellipsoid with 
equivalent normalized second order moments as the segmented nucleus area. The quotient of 
the total tissue thickness divided by the major axis of the cell nuclei was calculated for each 
core tissue section group used for DNA and RNA extraction. The nuclear count from the 
H&E section was then multiplied by this number to obtain the estimated total nuclear count 
in the tissue taken for extraction. For A cores this multiplication factor was 38.6 (220 µm/5.7 
µm), for B and C cores it was 40.7 (220 µm/5.4 µm).  
Cases Selected for DNA and RNA sequencing assay 
DNA and RNA isolated from A, B, and C cores from four 3-core study cases were selected 
for Miseq-based sequence analysis based on C Core (PAXgene) RQN values in an attempt to 
get a picture of the range of sequencing performance to be expected from PAXgene fixed 
prostate tissues. We studied two cases with the lowest recorded average RQN (PAX 84 and 
85, average RQNs 6 and 5.5 in two separate FA runs), and two cases with the highest 
recorded RQNs (PAX 91 and 96, average RQNs 6.7 and 6.9 respectively).  
36-gene targeted Miseq DNA sequencing assay 
AR and 35 other genes were targeted for capture and DNA sequencing (Supplemental Table 
11) in DNA isolated from A, B, and C cores in the 3-core study. Targeted sequence 
enrichment was performed using the SureSelectXT Target Enrichment System (Agilent 
Technologies, Santa Clara, CA) according to manufacturer’s instructions. Briefly, 200 ng of 
genomic DNA was sheared using a Covaris instrument (Covaris, Woburn, MA) to yield a 
fragment size of 150-200 bp. End repair, addition of the 3’-dA overhang, ligation of 
indexing-specific adaptors, hybridization to custom RNA baits, hybrid capture selection and 
index tagging were performed according to the Illumina paired-end sequencing library 
protocol. All recommended quality control steps were performed between steps. The 
multiplexed samples were sequenced on the Illumina Miseq platform using 150 bp paired-end 
reads. 
22-transcript targeted RNA sequencing assay   
A custom RNA sequencing panel was designed to cover all AR exons and introns to enable 
investigation of most common AR splice variants; 21 other gene transcripts were also 
included (Supplemental Table 12). Targeted sequence enrichment was performed using the 
SureSelectXT RNA Target Enrichment System (Agilent Technologies) according to 
manufacturer’s instructions. Briefly, poly(A) RNA was purified from 1 µg of total RNA and 
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fragmented chemically. In the following steps, samples were prepared using SureSelect 
Strand-Specific RNA Library Prep Kit to obtain adaptor-ligated cDNA library amplicons. 
Finally, hybridization to custom RNA baits, hybrid capture selection and index tagging were 
performed. All the AMPure XP bead purification steps were conducted as instructed. The 
multiplexed samples were sequenced on the Illumina Miseq platform using 150 bp paired-end 
reads. In five samples with RQN <6, (one C core with RQN 5.5, and four B core samples) 
modifications were made to the protocol as recommended by Agilent Technologies: 1) 
Instead of poly(A) RNA purification from 1 µg total RNA, Ribo-Zero Gold Magnetic Kit 
(Illumina, San Diego, CA) was used to remove rRNA from 2 µg of total RNA. 2) Instead of 
fragmenting the purified RNA at 94ºC for 8 min, RNA was denatured at 65ºC for 5 min. 3) 
All AMPure XP bead purification steps were performed using 1.8:1 bead volume to sample 
volume ratio. 4) Instead of 13 cycles in the pre-capture PCR, the number of cycles was 
increased to 14.  
DNA and RNA Sequence Analysis  
RNA-seq reads were aligned to human genome assembly GRCh37.2 (hg19) using Tophat2, 
version 2.0.1310. RNA sequencing coverage was computed using BedTools, version 2.26.011. 
For DNA damage analysis, DNA-seq reads were aligned to human genome assembly 
GRCh37.2 (hg19) using bowtie2, version 2.2.412. Duplicates were removed from DNA-seq 
alignments using samblaster tool, version 0.1.2213. SAMTools mpileup, version 1.3.114 was 
used for generating a pileup output of the alignments. Discrepancies used for the calculation 
of the single nucleotide changes (SNCs) were determined by parsing the number and identity 
of the bases corresponding to a particular position from the output using custom R scripts. 
Only high quality alignments with mapping quality score > 20 were used for the analysis. To 
identify   sequence artifacts, positions with variant allele frequency > 10% were excluded to 
minimize the number of true variants detected. In addition, positions with variant allele 
frequency < 1% were excluded as they were assumed to be sequencing errors. The frequency 
of each type of SNC was calculated by dividing the count of a given SNC by the total amount 
of the corresponding reference base calls and multiplying the result by 106. 
Statistics 
Quantitative differences between FF, FFPE and PFPE sample groups in the 3-core study were 
calculated using GraphPad software and groups were compared for statistical significance 
(P<0.05) using the unpaired t-test with Welch’s correction (GraphPad PRISM, version 5.02, 
GraphPad Software). The comparisons of PFPE RQN values in 4-core and 3-core study 
12 
 
groups (Supplemental Figure 1) were tested for significance using the two-tailed Wilcoxon 
rank-sum test with Gaussian approximation for p-value calculation to break ties in the data.  
RESULTS 
Clinical Data 
A standard set of intravenous drugs were used for anesthesia during RALP surgery 
(Supplemental Table 1). RALP pathology including Gleason grade and stage are contained in 
Supplemental Table 1. 
Tissue Quality Related Times and Temperatures 
Interval times and temperatures are compared for the 4-core and 3-core studies in Table 1. 
There are significant differences between the two studies in total prostate cooling time, total 
time from removal of the tissue from body to time in fixative, total time from patient under 
anesthesia to time in fixative and total time from first artery ligation to time in fixative (Table 
1).  
Tissue Cancer Cell Fraction 
Cancer cell fraction (CCF) was visually estimated based on a H&E face section whole slide 
image from each core by one pathologist (G.S.B.). In FF, FFPE, and PFPE cores, average 
(range in parentheses) CCF was 11 (0-50), 19 (0-80), and 8 (0-62) respectively. Welch test 
showed no significant difference in average CCF in the three types of tissue studied. 
Immunohistochemistry Overview 
Comparison of B, C and D (4-core study only) core PSA, ERG, Vimentin and 2IHC stains 
from the 3-core and 4-core studies were performed by two pathologists (T.T. and G.S.B). The 
staining protocols used for B, C, and D core sections were identical, no changes were made in 
the standard Fimlab clinical staining methods (Supplemental Methods). For these four IHC 
stains, no systematic difference in quality was detected, and all stain results appeared 
adequate for routine use. 
Surgical Pathologist Survey of H&E and 2IHC Histomorphology  
Overall, among the 5 surgical pathologists, the rate of correct identification of the fixative 
used based on the paired H&E and 2IHC image survey averaged 64% and 45% for tissue 
sections from FFPE and PFPE material respectively. The four pathologists with little or no 
previous experience comparing histology from FFPE and PFPE prostate material were 
essentially not able to reliably discern the fixative purely from the side by side H&E and 
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2IHC whole-slide images. The one surgical pathologist in the group with extensive prior 
experience comparing PAXgene and formalin-fixed prostate tissue histology side by side 
(T.T.) was significantly better at identifying fixative from histology, identifying 13/14 of the 
formalin fixed blocks correctly and 15/16 of the PAXgene fixed blocks correctly. In the 
survey, this pathologist noted that identification was mainly by red blood cell morphology 
(Supplemental Figure 2) and by a tendency to excess hematoxylin staining in cases he 
identified as PAXgene-fixed.  
Among the 5 pathologists, rated adequacy of the material for routine surgical pathology 
analysis was 100% and 96% for the FFPE and PFPE material respectively. One pathologist 
considered three of 16 PAXgene paired images inadequate for routine surgical pathology 
analysis, based on the carcinoma being partially AMACR negative in one case, and 
hyperchromasia being so intense in two cases that nucleoli were not visible.  The other 4 
pathologists considered all PAXgene H&E and 2IHC images adequate for routine surgical 
pathology. Representative examples of H&E and 2IHC staining in two cases where both 
FFPE and PFPE cores contained cancer are shown (Fig. 3, Supplemental Figure 3).  
No differences were detected in the overall quality of the H&E and 2IHC data in the 4-core 
and 3-core study material included in the survey.  
Nucleus Counts 
In the 3-core study, average nucleus counts per standard slide for each type of tissue were 
79839, 98609 and 86892 for FF (A), FFPE (B) and PFPE (C) cores, respectively. The counts 
were obtained by applying area and red/blue intensity based scaling to the counts given by 
nucleus detection. The correction factors used in scaling removed differences in average 
tissue areas and staining intensities between FF, FFPE,and PFPE cores. The total estimated 
nucleus count per 6.2 mm3 tissue volume was 3.1 x 106, 4.0 x 106 and 3.5 x 106 for FF (A), 
FFPE (B) and PFPE (C) cores, respectively (Supplemental Table 13).  
DNA Quality and Yield 
DNA isolated from FF, FFPE, and PFPE varied significantly in quality. In the 3-core study, 
average GQN for FF (A Core), FFPE (B Core), and PFPE (C Core) material was 7.9, 3.2, and 
6.2 respectively (all differences significant by Welch test p<0.0001, Fig. 4A). Average DNA 
fragment sizes for 3-core study A, B and C cores were 59, 20 and 41 kb respectively (Table 
2, Supplemental Figures 4A and 5A). The overall pattern of DNA quality differences 
between FF, FFPE, and PFPE material is illustrated in Figure 4B, where representative 
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Fragment Analyzer electropherogram tracings are superimposed on the same axis, and by 
comparing the results of running aliquots of the DNA from all 3-core cases on an agarose gel 
(Supplemental Figure 4A). Both FF and PFPE DNA populations are largely contained in bell-
shaped curves centered around the average, whereas FFPE DNA is notable for two peaks, one 
low 300 bp peak (about the length of DNA around two nucleosomes), and a larger peak at 20 
kb. DNA quality results were similar in the 4-core study material (Supplemental Table 1, 
Supplemental Figure 4B).  
 
Functional DNA quality of the 3-core study material was analyzed by Illumina FFPE QC 
assay. This method compares the qPCR Ct (threshold cycle) values between the analyzed 
samples and a reference DNA template. Average delta Ct values for FF (A Core), FFPE (B 
Core), and PFPE (C Core) material were -0.7, 1.9, and -0.6 respectively (Fig. 4C). FF and 
PFPE DNA performed similarly in this assay, while FFPE DNA performed significantly 
worse than either FF or PFPE DNA (Welch test, p< 0.0001).    
 
In the Miseq DNA assay, similar read counts were obtained for 3-core study FF, FFPE, and 
PFPE DNA. We compared rates of sequence artifact in FF, FFPE, and PFPE DNA. With the 
exception of a disproportional increase of C>A changes in two of the four FFPE-derived 
samples, the rate of various other artifacts is similar among the three sample types 
(Supplemental Figure 5B). 
 
Total DNA yield from unit volumes of FF, FFPE, and PFPE also varied significantly. In the 
3-core study, average DNA yield from our standard 6.2 mm3 tissue volume from FF (A 
Core), FFPE (B Core), and PFPE (C Core) material averaged 1.3 µg, 2.8 µg and 2.7 µg 
respectively. DNA yield from FF material was significantly lower than FFPE and PFPE 
(Welch test, p<0.001 and p<0.01, respectively), and total DNA yields for FFPE and PFPE 
material were nearly identical (Supplemental Figure 5C).   
 
Using the estimated total nuclear count derived from image analysis of face sections from 
each core sample 6.2 mm3 tissue volume, FF (A Core), FFPE (B Core), and PFPE (C Core) 
average DNA yield per nucleus was 0.41 pg (picogram), 0.69 pg and 0.78 pg respectively 
(Fig 4D). Variation in yield per nucleus within each of the three (FF, FFPE, and PFPE) 
sample types was low for FF samples, and higher for FFPE and PFPE samples.  
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RNA Quality and Yield 
Total RNA isolated from FF, FFPE, and PFPE varied significantly in quality. Overall RNA 
quality features from A, B and C core tissues in the 3-core study are summarized in Table 2. 
In the 4-core study, average RQN for A, B, C core (PFPE processed in Citadel research 
processor) and D core (PFPE processed in Fimlab Pathos processor), were 9.1, 2.8, 4.6 and 
5.1 respectively (Supplemental Table 1). In the 3-core study, average RQN for FF (A Core), 
FFPE (B Core), and PFPE (C Core) material was 8.7, 2.6, and 6.3 respectively (all 
differences significant by Welch test p<0.0001, Fig. 5A). RQN values from the PAXgene-
fixed C cores inversely correlated with the time the cores sat in Stabilizer before processing 
(R= -0.75, p<0.001). There was no correlation between the 3-core study RQN or GQN values 
from matched FF, FFPE and PFPE cores (Supplemental Figure 6A). In addition, the RNA 
DV200 values (the percentage of RNA over 200 nucleotides in size) for FF, FFPE and PFPE 
cores were 81%, 50% and 76%, respectively (Table 2). The overall pattern of RNA quality 
differences between FF, FFPE, and PFPE material is illustrated in Figure 5B, where 
representative Fragment Analyzer electropherogram tracings are superimposed on the same 
axis. FF RNA contains sharp 18S (2 kb) and 28S (5 kb) ribosomal RNA peaks, PFPE RNA 
also shows a similar 18S peak and a 28S peak lower in amplitude.  FFPE RNA 18S and 28S 
peaks are not discernible in this tracing. 
 
Targeted sequencing of RNA transcripts showed decreased performance of FFPE RNA. 
While the mean total number of reads was similar in the three fixation groups (>2.5x106), the 
FFPE (B core) samples had a lower distribution of raw coverage at each position of target 
transcripts compared to both FF (A core) and PFPE (C core) samples (Fig. 5C). Comparing 
all 3-core study RNA samples, we found strong correlation between RQN values and median 
coverage (R= 0.87, p<0.001, Pearson correlation test).   
 
Total RNA yield from unit volumes of FF, FFPE, and PFPE varied significantly. In the 3-
core study, average RNA yield from our standard 6.2 mm3 tissue volume from FF (A Core), 
FFPE (B Core), and PFPE (C Core) material averaged 4.3 µg, 3.7 µg and 7.8 µg respectively. 
RNA yield from PFPE material is significantly higher than for FFPE or FF material (Welch 
test, p=0.0002, p=0.0005, respectively), and total RNA yields for FF and FFPE material are 
not significantly different (Welch test, p=0.39, Supplemental Figure 6B).    
 
16 
 
In the 3-core study, using the estimated total nuclear count derived from image analysis of 
face sections from each core sample 6.2 mm3 tissue volume, FF (A Core), FFPE (B Core), 
and PFPE (C Core) average RNA yield per nucleus was 1.40 pg, 0.94 pg and 2.24 pg 
respectively (Fig 5D).   
Materials and Storage Costs 
The average prostate weight in the combined 4-core and 3-core studies was 55.6 g. Qiagen 
recommends a ratio of tissue volume to PAXgene fixative volume of “at least 1:10” (Qiagen 
PAXgene Tissue Fix Product Circular). Most recent costs in our locality for 600 mL 
PAXgene fixative (170 €/190 USD) and 600 mL diluted PAXgene stabilizer (27 €/30 USD) 
are 18x higher than our local cost for 600 mL of Formalin (11 €/12 USD). Our local cost for 
equal 3kg of Paraplast Xtra paraffin (120 €/134 USD) is more than 6x higher than cost for the 
same amount of Histowax (18 €/20 USD), the standard paraffin used in Fimlab.  In addition 
to materials costs, storage costs for PFPE tissues are higher, since they must be stored at 4°C 
or below to reduce degradation of biomolecule quality (Qiagen PAXgene Tissue Fix Product 
Circular).   
DISCUSSION 
Comparative analysis of Fresh Frozen, FFPE, and PFPE tissue sample histology, IHC, DNA 
and RNA quality from 36 prostatectomy specimens suggests that it is feasible to use 
PAXgene fixation and processing of prostate tissue for combined molecular research and 
diagnostic surgical pathology. PFPE tissues collected and processed under conditions similar 
to those in the second (3-core) phase of the study reported here will provide significantly 
better DNA and RNA quality and yield as compared to FFPE tissues, therefore providing 
support for tighter linkage between histomorphology and molecular genetic analysis of 
prostate cancer phenotypes, while providing sufficient quality histology for standard surgical 
pathology radical prostatectomy diagnostics.  
 
The PFPE RNA quality obtained in the 3-core study (16 patients, average RQN 6.3) was 
significantly better than what was obtained in the initial 4-core study (20 patients, average 
RQN 5.1). In the 3-core study, a new dedicated tissue processor (Leica TP1020), lower 
melting point paraffin (ParaplastXtra) and a different deparaffinization method (Xylene at 
Room Temp) was used. Further study is needed to determine which of these three changes 
are most important to obtaining improved RNA quality. Another factor could be the 
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significantly reduced time to fixative, surgical time, and post-arterial ligation times (Table 1) 
in the 3-core cohort (improvements that were detected after the study and not specifically 
attempted). However, RNA quality in the FF tissues from the 4-core (average RQN 9.1) and 
3-core cohort (average RQN 8.7) were not statistically significantly different, and therefore 
the RNA quality upon arrival in surgical pathology was already at a similar maximum in the 
4-core study. Improvements in downstream RNA quality in the 3-core study are more likely 
due to some or all of the downstream changes specific to the 3-core study.  
 
To our knowledge, this is the first study to compare DNA and RNA yield per nucleus using 
different processing methods. Surprisingly, we found that DNA yield per nucleus in FFPE 
(0.69 pg) and PFPE (0.78 pg) is similar (although FFPE DNA is markedly degraded 
compared to PFPE DNA), and DNA yield per nucleus from FF tissue using similar column-
based extraction methods is significantly lower (0.41 pg) than both PFPE and FFPE. Why 
DNA yield per nucleus is lower in FF tissue is not clear. Differences in the column-based 
extraction protocols could account for some of these differences, but they are similar in their 
basic components and unfortunately are not open to scientific analysis since the content of the 
various solutions is not provided by Qiagen. A normal diploid human male cell is calculated 
to contain 6.1 pg of nuclear DNA15. Mitochondrial DNA is an important component of 
cellular DNA content, but contributes less than 1% of the total weight of DNA per cell16,17. 
Cancer nuclei are often aneuploid (with >6.1 pg of DNA per nucleus), but average cancer cell 
fraction among the three core types was similar. Our study therefore shows that the typical 
column-based extraction methods used here yield no more than 15% of the DNA available in 
the tissue. There is substantial room for DNA yield improvement, and we advocate using 
yield per nucleus in future DNA and RNA extraction studies to identify improvements.   
 
The RNA yield (quantity) per nucleus was 1.40 pg with FF, 0.94 pg with FFPE, and 2.24 pg 
with PFPE. Surprisingly, PFPE provided better yield per nucleus than either FF or FFPE 
tissues. We detected no significant difference in cancer or other cell content in the A, B, and 
C cores, and therefore we do not think these differences are due to different cellular makeup 
among FF, FFPE, and PFPE cores. Why PFPE provided significantly greater RNA yield per 
nucleus than FF or FFPE tissue is not clear and if this is confirmed in future studies, could 
provide a rationale for preferred use of PAXgene processing of prostate biopsy material 
where cancer cell nuclei for molecular analysis are often relatively low in number. 
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In terms of quality, we found that PFPE DNA and RNA quality is significantly better than 
FFPE DNA and RNA quality, but also worse than DNA and RNA quality from FF tissue. 
Further tweaking of PFPE processing methods could yield even more intact DNA and RNA. 
A first step could be to isolate DNA from tissue fixed in PAXgene but not paraffin 
embedded. This could isolate whether PAXgene acetic acid causes strand breaks, or whether 
strand breaks occur during the heating and paraffin diffusion during processing and 
embedding or during paraffin extraction, or both.  
 
Our results unexpectedly suggest how RNA quality routinely obtained from FFPE tissue 
could theoretically be markedly improved. Average FFPE RQN obtained in the 3-core study 
was only 2.6, but it ranged widely, from 1.1 to 5.4 (Supplemental Figure 6A), while RQN in 
FF and PFPE tissue from the same prostates were relatively stable. The FFPE tissues 
processed in the 3-core study were part of the regular surgical pathology workflow, meaning 
that while the tissues all contained RNA of high quality to start with and processing 
chemicals and times were similar among all FFPE blocks, the time the blocks sat in formalin 
prior to processing and in the processor at elevated temperature at the end of processing but 
before embedding, and the time maintained at elevated temperature during embedding likely 
varied substantially from case to case since this is currently not standardized. A controlled 
study comparing prostate RNA quality in tissues exposed to variable time in formalin and 
variable time in molten paraffin during embedding would test this hypothesis, and if true, 
average RNA quality in FFPE could be elevated to the RQN 4-5 range if surgical pathology 
routines can be modified to obtain the identified optimal times.  
 
Reports of DNA sequence artifacts associated with formalin fixation18 prompted us to 
compare sequence artifacts in matched FF, FFPE, and PFPE samples from four cases. 
Sequence from FF and PFPE shared a similar low rate of artifacts (Supplemental Figure 5B), 
another positive point for PFPE. Surprisingly, FFPE material from this study did not contain 
an excess of C>T transitions as found in 42-100% of samples in several prior studies18 but 
two of the four FFPE samples did show an excess of C>A transversion artifacts of unknown 
origin. C>A artifacts were reported by Costello et al19 to be associated with oxidation of 
DNA by acoustic shearing, a standard step prior to high throughput sequencing. In our study 
acoustic shearing was performed using standard settings for all DNA samples sequenced 
(from FF, FFPE, and PFPE tissues), so this is not likely the source of this artifact in our 
study.  Moreover the C>A artifacts observed in the current study did not occur in the 
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CCG>CAG context reported by Costello et al19.  The lack of excess of C>T base transitions 
detected in FFPE DNA in the current study, consistent with previous reports where such 
artifacts are less commonly found in tissues fixed in buffered formalin less than 72 hours and 
in younger tissue blocks20,21, also supports the idea that such artifacts could be routinely 
minimized with better standardization of FFPE processing. However, we should add that 
excess C>T artifacts may have been present in the FFPE DNA, but not detected by our assay. 
FFPE DNA C>T base transitions are often caused by deamination of cytosine, leading to 
formation of uracil and the subsequent incorporation of an adenine base in the opposite 
strand. Some DNA polymerases recognize deaminated cytosine residues and stall 
amplification until the correct base is incorporated, thus preventing amplification of strands 
containing this artifact22. The ability of the Herculase II polymerase used in our sequencing 
assay to recognize deaminated bases is thus an additional possible reason for the low number 
of C>T artifacts detected in these FFPE samples23. 
 
There are nuances and limitations of the study worth mentioning. This study compared 
histology and IHC between matched FFPE and PFPE tissues only at a general level, it did not 
compare ability to do Gleason grading or surgical margin status determination. Five surgical 
pathologists reviewing paired H&E and 2IHC stained whole slide images in a blinded fashion 
rated 100% of FFPE material and 96% of PFPE material adequate for diagnostic surgical 
pathology. Comparison of Gleason grading and nuclear morphology was not performed in the 
current study because the comparison tissues were not sufficiently close to each other. Future 
studies could include “kissing” sections (one FFPE, one PFPE) to allow reasonably sound 
Gleason grading comparisons. Analysis of surgical margin status in surgical pathology 
laboratories where whole prostates are initially fixed overnight in formalin is quite different 
from analysis of surgical margins in prostates that are fully sectioned fresh, just after inking, 
as they must be to obtain high quality RNA with PAXgene fixation. This could also 
potentially be addressed in future studies by comparing margin status in “kissing” sections 
only microns apart.  
 
In order to scientifically compare histologic adequacy of paired FFPE and PFPE material in 
future studies, H&E staining for PFPE sections should be adjusted to match standard H&E 
staining in FFPE tissue sections. In the current study, in PFPE tissue sections, a reduction of 
eosin concentration of 50% and a reduction in eosin exposure time from 60 seconds to 5 
seconds achieved similar eosin intensity between PFPE and FFPE sections. Hematoxylin 
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concentration and exposure time was not decreased in the current study, but one of the 
pathologists noted excess hematoxylin intensity and relative reduction of hematoxylin 
concentration or exposure time for PFPE sections should be considered in future studies.  
 
The IHC comparison results are consistent with previously reported findings that staining 
PFPE tissue using IHC protocols developed with FFPE tissue often, but do not always give 
similar results. Further research is needed to determine which IHC protocols require 
adjustment for routine diagnostic use in PFPE tissue. 
 
In summary, we found that preservation of prostate histomorphology in hematoxylin and 
eosin (H&E) stained PFPE tissue is comparable to that of FFPE and appears sufficient to 
support routine diagnostic surgical pathology. IHC-based detection of prostate cancer 
markers PSA, p63 + Ck5/6 and ERG is possible in PFPE prostate tissue without modification 
of protocols optimized for FFPE tissue. RNA and DNA isolated from PFPE tissue is 
substantially more intact compared to FFPE, RNA yield is greater from PFPE than FFPE 
tissue, and PFPE DNA and RNA is amenable to next generation sequencing (NGS) based 
methods of analysis. We propose the use of per-nucleus yields of DNA and RNA as 
benchmarks for future studies aiming to advance the basic science of tissue DNA and RNA 
preservation, extraction and analysis.    
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FIGURE LEGENDS   
 
 FIGURE 1. Study design. Overview of the methods used in the 4-core study (A) and 
subsequent 3-core study (B). Results from both phases of the study are reported, with 
emphasis on the 3-core study, where improved RNA quality was obtained. FF: Fresh frozen; 
FFPE: Formalin-fixed paraffin embedded; PFPE: PAXgene-fixed paraffin embedded. 
 
FIGURE 2. Overview of core sectioning. Consecutive sections were cut from each of the 
cores for H&E, IHC and nucleic acid extraction as indicated in the figure and in Materials 
and Methods.  FF: Fresh frozen; FFPE: Formalin-fixed paraffin embedded; PFPE: PAXgene-
fixed paraffin embedded. 
 
FIGURE 3. Representative histomorphology of formalin-fixed paraffin-embedded (FFPE) 
and Paxgene-fixed paraffin-embedded (PFPE) tissue containing cancer. Representative 
examples of H&E (left) and 2IHC (CK5/6, p63 and AMACR, right) stained FFPE (A, B) or 
PFPE (C, D) cores from case PAX 89. 100 micron width reference bar shown. See 
Supplemental Figure 3 for a second set of representative images from PAX 69. 
 
FIGURE 4. Genomic DNA yield and quality. A) Genomic Quality Number GQN measured 
with Fragment Analyzer are shown for A, B and C cores in the 16 cases in the 3-core study. 
B, Fragment Analyzer DNA tracings from representative samples from A (blue), B (red) and 
C (green) cores (RFU, Relative Fluorescence Units). C, qPCR-based quality control (FFPE 
QC Kit, Illumina) ΔCt values (Core DNA Ct-QC kit template DNA Ct) for amplified DNA. 
A ΔCt value of ≤ 2 is considered good quality DNA. D, Estimated picogram DNA yield per 
nucleus based on nucleus counts performed as described in Materials and Methods. Mean and 
SD shown for each group (n=16), ** p<0.01, *** p<0.001. FF: Fresh frozen; FFPE: 
Formalin-fixed paraffin embedded; PFPE: PAXgene-fixed paraffin embedded. GQN values 
in the 20-case 4-core study were similar. 
 
FIGURE 5. Total RNA yield and quality. A, RNA Quality Number (RQN) measured with 
Fragment Analyzer are shown for A, B and C cores in the 16 cases in the 3-core study. B, 
Fragment Analyzer RNA tracings from representative samples from A (blue), B (red) and C 
(green) cores. C, RNA sequencing of RNA isolated from A, B and C core tissue from four 
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representative cases (PAX 84, 85, 91 and 96). Boxplot displaying the distributions of 
coverage at each position of 22 target transcripts in MiSeq (Illumina) RNA. The values are 
log2-transformed for better visualization. The boxes span the interquartile range (IQR) of the 
values, with the lines inside the boxes showing the medians, and whiskers above and below 
the boxes showing the locations of the minimum and maximum data points within 1.5 times 
the IQR. D, Estimated picogram RNA yield per nucleus. Mean and SD are shown for each 
group (n=16).* p<0.05, ** p<0.01, *** p<0.001. FF: Fresh frozen; FFPE: Formalin-fixed 
paraffin embedded; PFPE: PAXgene-fixed paraffin embedded. 
 
  
 
TABLES 
 
Table 1. Key tissue collection time, weight, and temperature data means (standard deviations) from the 4-core and 3-core studies.  
Phase of Study 
Time between 
leaving body and 
arriving in 
pathology 
(h:mm)  
Prostate 
weight 
(grams) 
Prostate core 
temperature on 
arrival in 
pathology 
laboratory 
(Celsius) 
Prostate core 
temperature low 
point after cooling   
(Celsius) 
Total cooling 
time (h:mm) 
Total time from 
removal from 
body to time in 
fixative (h:mm) 
Total time from 
patient start 
anesthesia to 
time in fixative 
(h:mm) 
Total time from 
first artery 
ligation to time in 
fixative (h:mm) 
Total operating 
time from first 
trocar to time 
prostate out of 
body (h:mm) 
 
4-core (initial 
phase, 20 
cases over 6 
weeks in 2015  
 
0:15 (0:13) 56.7 (16.6) 27.7 (3) 13.8 (2.3) 0:11 (0:06) 0:52 (0:13) 3:35 (0:57) 1:44 (0:29) 2:21 (0:49) 
 
3-core (second 
phase, 16 
cases over 2 
weeks in  2015  
 
0:14 (0:11) 54.2 (17) 27.6 (2.1) 14.6 (0.9) 0:07 (0:03) 0:40 (0:13) 2:52 (0:46) 1:23 (0:20) 1:55 (0:40) 
p-value n.s. n.s. n.s. n.s. p<0.05 p<0.05 p<0.05 p<0.05 n.s. 
 
 
 
 
 
 
  
 
Table 2. Summary of genomic DNA and total RNA quality for A, B and C core groups in the 
3-core study. 
Core 
group 
Fixation 
method 
Extraction 
method 
(Qiagen) 
DNA yield  
(ng)/ 6.2 
mm3 
DNA 
GQN 
Average 
DNA  
fragment 
length (bp) 
RNA yield 
(ng)/6.2 
mm3 
RNA 
RQN 
RNA 
DV200 
A Fresh Frozen (FF) 
Allprep 
Universal 1261 ± 470 
7.9 + 
0.4 58939 ± 2989 
4341  ± 
1683 
8.7 ± 
0.9 
80.8 
±3.8 
B 
Formalin-
fixed 
paraffin 
embedded 
(FFPE) 
Allprep 
FFPE 2786 ±1383 
3.2 + 
0.5 19680 ± 2418 3726 ± 2242 
2.6 ± 
1.2 
49.8 
±13.4 
C 
PAXgene-
fixed 
paraffin 
embedded 
(PFPE) 
Paxgene 
Allprep 
2718 ± 
1562 
6.2 + 
0.9 41274 ± 9216 7806 ± 2970 
6.3 ± 
0.3 
75.5 
±3.4 
GQN: Genomic Quality Number; RQN: RNA Quality Number; DV200: percentage of RNA over 200 nucleotides 
in size 
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SUPPLEMENTAL METHODS 
 
Processing Chemicals 
Chemicals used in tissue processing and staining listed in the tables below used in the 4-core study Pathos 
DELTA and Citadel processors were the same products from the same manufacturers but not the same lot 
numbers due to different ordering logistics in each location. Processing and staining chemicals used in the 3-
core study Pathos DELTA and Leica TP1020 processors were from the same manufacturers and lot 
numbers.  
 
Standard Fimlab Prostate External Inking for Surgical Margin Analysis 
Using correct inking technique (complete coverage using  cotton applicator (Ref 120783, Selefa OneMed) 
then dried with paper towels) black ink (CAT# WAK-HM-B-3, WAK-Chemie Medical GmbH) was placed 
on the surface of the left side and on the whole posterior surface, blue ink (CAT# WAK-HM-BL-5, WAK-
Chemie Medical GmbH) on the surface of the right side and green ink (CAT# WAK-HM-G-1, WAK-
Chemie Medical GmbH) on the anterior apex and anterior base. Inking was performed with “clean” 
technique, wearing non-sterile gloves, non-sterile cotton applicators, and non-sterile ink as supplied by the 
manufacturer.  
 
Web-Based Blinded, Randomized Survey of FFPE vs PAXgene fixed tissue histology 
All cores containing cancer from the 3-core and 4-core study were included in the survey.  Cores containing 
no cancer were excluded since adenocarcinoma is the main focus of surgical pathology evaluation of radical 
prostatectomy specimens. Provided onscreen to each pathologist with the survey: 
 
Title of Survey:  Surgical Pathology Adequacy Survey 
Instructions:  8mm and 6mm punches taken from 6mm thick radical prostatectomy transverse sections were 
fixed in either PAXgene or Formalin using standard procedures, and sections were cut for H&E and 2IHC 
(AMACR, p63 and cytokeratin 5/6) staining. With each question you will be presented with the H&E and 
2IHC stain from the same core. The images of the H&E and 2IHC sections are from the same block but may 
not be in the same orientation. Questions refer to each HE/2IHC pair. 
 
Questions with each zoomable image pair from the same tissue block, with no identifier provided (H&E on 
left, 2IHC stain on right): 
1 - What is your best estimate of how the source tissue block was prepared? (required dropdown selection:  
Formalin-Fixed Paraffin-Embedded or PAXgene-fixed Paraffin-Embedded) 
2 - What visual clues are you using to identify the tissue as processed in this way? (optional free text field) 
4 
 
3 - Taking into account the H&E and 2IHC staining, does the quality appear adequate for routine radical 
prostatectomy surgical pathology analysis, such as identification of cancer cells, and Gleason scoring? 
(required dropdown selection: yes/no) 
4 - Please state what is not adequate (optional free text field) 
 
Qiagen Kit Extraction modifications 
Isolation of 3-core study FFPE (B Core) and 4-core study FFPE (B core) and PFPE (C and D core RNA and 
DNA was done using Qiagen’s Allprep DNA/RNA FFPE kit (cat no 80234) or the PAXgene Tissue Allprep 
DNA/RNA/miRNA method (Qiagen’s PX10 Supplemental protocol) according to manufacturer’s 
instructions, apart from the deparaffinization steps. 1400 µl heptane was added to the cut paraffin sections, 
the tubes were vortexed vigorously for 10s and incubated 20 min at 37°C. 70 µl methanol was added, the 
samples vortexed and centrifuged for 2 min at 9000 x g. The supernatant was carefully removed using a 
pipet, 1.4 ml ethanol added to the pellet followed by vortexing and centrifugation for 2 min at full speed. 
The supernatant was removed and the ethanol wash repeated.  
 
3-core PFPE (C core) DNA and RNA were isolated with the PAXgene Tissue Allprep DNA/RNA/miRNA 
method (PX10 supplementary protocol) according to manufacturer’s instructions, apart from a small 
modification in the deparaffinization step. 650 ul xylene was added to cut paraffin sections, the tubes were 
vortexed vigorously for 20s and incubated 10 min on the benchtop before continuing with ethanol washing 
according to protocol. 
 
Immunohistochemistry staining protocols:  
All immuno stains (2IHC, PSA, ERG and Vimentin) were done at Fimlab according to their standard 
staining protocols for their own diagnostic purposes and counterstained with hematoxylin.  
 
PSA-stain:  
• Automated Bond III technology  
• Leica Bond™ Polymer Refine Detection-kit  
• Pretreated 30min with Bond Epitope Retrieval Solution 1  
• Hybridized with Dako (A0562 Clone, 1:15000 dilution) against PSA  
 
ERG-stain:  
• Automated Bond III technology  
• Leica Bond™ Polymer Refine Detection-kit  
• Pretreated 30min with Bond Epitope Retrieval Solution 2  
• Hybridized with Biocare Medical antibody (CM421C Clone: 9FY, 1:500) against ERG.   
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LeicaVimentin-stain:  
• Automated Bond III technology  
• Leica Bond™ Polymer Refine Detection-kit  
• Pretreated 20min with Bond Epitope Retrieval Solution 1  
• Hybridized with Leica RTU PA0033 (Clone: SRL33) against Vimentin.  
 
2IHC-stain (AMACR, p63 and cytokeratin 5/6):  
• Automated Ventana Benchmark GX technology  
• Optiview-kit (brown for p63 and KRT5/6) and Ultraview Alkaline Phosphatase Red (for AMACR) 
• AMACR-anitibody: Sigma Aldrich HPA019527-100UL (Polyclonal, 1:2000)  
• p63-antibody: Bio SB (BSB5853, Clone: 4A4, 1:100) 
• cytokeratin 5/6 antibody: Zymed 18-0267 (Clone: D5/16 B4, 1:100) 
 
SUPPLEMENTAL FIGURES 
 
Supplemental Figure 1. 3- and 4-core study PFPE RNA quality. Mean and SD are shown, n=16 for 3-core 
and n=20 for 4-core study samples. **p<0.01,*** p<0.001.  
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Supplemental Figure 2. Red blood cell morphology. Representative examples of H&E stained red blood 
cells from FFPE (A) and PFPE (B) cores from case PAX69. 10 micron width reference bar shown. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Supplemental Figure 3. Histomorphology of formalin-fixed paraffin-embedded (FFPE) and Paxgene-fixed 
paraffin-embedded (PFPE) tissue containing cancer. Representative examples of H&E (left) and 2IHC 
(CK5/6, p63 and AMACR, right) stained FFPE (A, B) or PFPE (C, D) sections from case PAX 69. 100 
micron width reference bar shown. 
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Supplemental Figure 4. Genomic DNA agarose gel electrophoresis. A, 3.0 µL of each undiluted, original 3-
core study DNA sample (PAX 82-97 A, B and C cores) were loaded with 6x DNA loading buffer into a 
0.6% agarose gel with 0.5x SYBR Safe DNA dye (Thermo Scientific). Electrophoresis was performed in 0.5 
X TBE buffer at 80 V for 70 min, after which the gel was visualized under UV-light (800 ms). The sample 
labels for all PAX cores are shown above each well and DNA size markers are illustrated on the left and 
right sides of the figure. 2 µL of MassRuler™ High Range DNA Ladder (Thermo Scientific) is used as 
marker. B, 3.0 µL of each undiluted, original 4-core study DNA sample was loaded with DNA loading 
buffer into 0.6% Agarose gel. Electrophoresis was performed in 0.5 X TE buffer, EtBr 165 µg/mL, at 120 V 
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for 50 min after which the gel was visualized under UV-light (720 ms). M1: 2 µL of MassRuler™ High 
Range DNA Ladder (Thermo Scientific), M2: 2 µL of 1 kb DNA Ladder (NEB), M3: 2 µL of GeneRuler™ 
100 bp DNA Ladder (Thermo Scientific).  
 
 
 
Supplemental Figure 5. Genomic DNA yield and quality. A, Average DNA fragment length (bp) of two 
Fragment Analyzer measurements is shown for each individual core sample for the A, B and C cores. B, 
Sequencing artefacts in DNA MiSeq. The bars show the frequencies of the indicated base  
changes per million corresponding correct base calls (the count of A>A, C>C, G>G, or T>T base calls) in 
the 1-10% variant allele frequency range. C, Genomic DNA yield per 6.2 mm3 tissue volume measured with 
Qubit 2.0. Mean and SD are shown for each group (n=16). **p<0.01, *** p<0.001. FF: Fresh frozen; FFPE: 
Formalin-fixed paraffin embedded; PFPE: PAXgene-fixed paraffin embedded. 
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Supplemental Figure 6. Nucleic acid quality and yield. A, RQN and GQN values from matched A, B and C 
samples ordered in decreasing RQN values of A cores from the 3-core study. B, Total RNA yield per 6.2 
mm3 tissue volume measured with Fragment Analyzer. Mean and SD are shown for each group (n=16). *** 
p<0.001. FF: Fresh frozen; FFPE: Formalin-fixed paraffin embedded; PFPE: PAXgene-fixed paraffin 
embedded. 
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SUPPLEMENTAL TABLES 
 
Supplemental Table 1. Summary of 4-core and 3-core methods and results. 
  
4-core study (first phase) 3-core study (final phase) 
RALP Patient Cohort 20 men  16 men  
Fixation method of 
whole mount donor 
tissue section 
Tissue section placed  between two pieces of 
nylon and polyester sheets inside a 200ml 
container, keeping the tissue flat during fixation. 
Tissue section placed in a Supa Mega Slim 
white cassette (CellPath, EAN 0102-02A)  
Core punches 4 cores, 8 mm diameter, taken as depicted in 
Fig. 1A 
3 cores, 6 mm diameter taken as depicted 
in Fig. 1B. Coring was shifted to the 
posterior side to increase likelihood of 
having cancer in the core, since prostate 
cancer is more often found posteriorly. 
Core diameter was decreased since the 8 
mm cores suggested smaller cores would 
provide sufficient area for histologic 
assessment while allowing the three cores 
to sample more closely related areas of 
each prostate. 
Tissue processing B cores: Fimlab pathology laboratory standard 
Pathos DELTA  protocol for formalin tissue; C: 
Citadel 2000 processor, optimized for PAXgene 
tissue; D: Pathos DELTA processor, optimized for 
PAXgene tissue 
B cores: Fimlab pathology laboratory 
standard Pathos DELTA  protocol for 
formalin tissue ; C: Dedicated Leica TP1020 
optimized for PAXgene tissue  
Embedding Paraffin B, C, and D cores: Histowax, Histolab B cores: Histowax, C Cores: Paraplast Xtra, 
P3808 Sigma-Aldrich 
Deparaffinization B, C, and D cores: Heptane  (see Supplemental 
Methods above) 
B cores: Heptane, C cores: Xylene (see 
Supplemental methods above) 
H&E staining Standard staining protocol for FF sections (Supp 
Table 7). The same protocol for B, C and D cores 
(Supp Table 6). 
C  (Supp Table 9) and A core (Supp Table 
10) protocols optimized to match Fimlab 
standard B core staining (Supp Table 8) 
protocol intensities. 
Scanning Olympus BX51 with Olympus UplanSApo 40x 
objective and Surveyor Software, Objective 
Imaging Ltd. 
Hamamatsu Photonics Nano Zoomer XR 
C12000 automated scanner with 
0.23µm/pixel resolution.    
Anesthesia agents and 
other drugs during 
surgery 
Cefuroxine 1,5 g, Propofol 2%,  
Remifentalil 50mg, Rocuron 30-50 mg 
 
Cefuroxine 1,5 g, Propofol 2%, Remifentalil 
50mg, Rocuron 30-50 mg 
Surgical Pathology 
Report Gleason grades (# 
patients) 
3+3 (2), 3+4 (11), 4+3 (5), 4+4 (1), 4+5 (1)  
 
3+4 (9), 4+3 (4), 4+4 (1), 4+5 (1), 5+3 (1)  
pTNM staging (# 
patients) 
pT2a (1), pT2c (11), pT3a (7), pT3b (1) pT2a (1), pT2b (3), pT2c (2), pT3a (7), pT3b 
(3) 
DNA Quality Average GQN:  FF (A cores) 8.2, FFPE (B cores) 
4.0  PFPE (C cores) 6.8 and PFPE (D cores) 7.0 
Average GQN:  FF (A cores) 7.9, FFPE (B 
cores) 3.2 and PFPE (C cores) 6.2.  
RNA Quality Average RQN:  FF (A cores) 9.1, FFPE (B cores) 
2.8  PFPE (C cores) 4.6 and PFPE (D cores) 5.1 
Average RQN:  FF (A cores) 8.7, FFPE (B 
cores) 2.6 and PFPE (C cores) 6.3.  
DNA Quantity FF (A cores) 0.6 µg, FFPE (B cores) 0.8 µg, PFPE 
(C cores) 1.1 µg and PFPE (D cores) 1.4 µg per 
6.0 mm3 tissue volume  
Per nucleus (not done) 
FF (A cores) 1.3 µg, FFPE (B cores) 2.8 µg 
and PFPE (C cores) 2.7 µg per 6.2 mm3 
tissue volume  
FF 0.41 pg, FFPE 0.69 pg and PFPE 0.78 pg  
per nucleus 
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RNA Quantity FF (A cores) 5.2 µg, FFPE (B cores) 2.7 µg, PFPE 
(C cores) 4.9 µg and PFPE (D cores) 5.4 µg per 
6.0 mm3 tissue volume 
Per nucleus (not done) 
FF (A cores) 4.3 µg, FFPE (B cores) 3.7 µg 
and PFPE (C cores) 7.8 µg per 6.2 mm3 
tissue volume  
FF 1.40 pg, FFPE 0.94 pg and PFPE 2.24 pg 
per nucleus 
 
Supplemental Table 2. Pathos DELTA tissue processing protocol for formalin-fixed B cores in the 3-core 
and 4-core studies. 
Phase Phase Name Reagent Phase type Heating Vacuum Step Time h:min Temp Pressure 
1 Fixation Formalin Fixation MW and resistance no 1 0:30 40C - 
            2 0:45 40C - 
            3 0:30 50C - 
            4 0:45 50C - 
2 Flushing 
Flushing Mix 
(~70% 
Ethanol) 
Flushing no no 1 0:05 - - 
3 Rinsing1 Ethanol Rinsing MW and resistance no 1 0:10 40C - 
4 Rinsing2 Ethanol Rinsing MW and resistance no 1 0:10 40C - 
            2 0:05 40C - 
5 Ethanol Ethanol 
Dehydration, 
clearing, 
other 
MW and 
resistance no 1 0:20 55C - 
            2 1:50 55C - 
6 Isopropanol Isopropanol 
Dehydration, 
clearing, 
other 
MW and 
resistance no 1 0:20 65C - 
            2 3:40 65C - 
7 Isopropanol2 Isopropanol2 
Dehydration, 
clearing, 
other 
MW and 
resistance no 1 0:20 65C - 
            2 0:40 65C - 
            3 0:20 68C   
            4 3:10 68C - 
8 Vaporization - Vaporization no yes 1 0:03 - 600 mbar 
9 Wax impregnation Wax Wax 
Only 
resistance yes 1 0:30 70C 
500 
mbar 
            2 0:20 70C 400 mbar 
            3 0:20 70C 300 mbar 
            4 0:20 70C 200 mbar 
            5 0:20 70C 150 mbar 
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            6 4:00 65C 100 mbar 
            7 3:00 65C 800 mbar 
 
Supplemental Table 3. Citadel 2000 (69810051 Issue 18) tissue processing protocol for PAXgene-fixed C 
cores in the 4-core study. 
Step Solution Time h:min Temp 
1 Ethanol 80% 0:30 RT 
2 Ethanol 96%  0:30 RT 
3 Ethanol 96%  0:30 RT 
4 Ethanol 100% 1:00 RT 
5 Ethanol 100% 1:00 RT 
6 Xylene 1:00 RT 
7 Xylene 1:30 RT 
8 Histowax 1:15 60°C 
9 Histowax 1:15 60°C 
 
Supplemental Table 4. Pathos DELTA tissue processing protocol for PAXgene-fixed D cores in the 4-core 
study. 
Phase Phase Name Reagent Phase type Heating Vacuum Step Time h:min Temp Pressure 
1 80% EtOH 80% Ethanol 
Dehydration, 
clearing other no no 1 0:30 - - 
2 96% EtOH1 96% Ethanol1 
Dehydration, 
clearing other no no 1 0:30 - - 
3 96% EtOH2 96% Ethanol2 
Dehydration, 
clearing other no no 1 0:30 - - 
4 100% Ethanol1 Ethanol (ABS)1 
Dehydration, 
clearing other no no 1 1:00 - - 
5 100% Ethanol2 Ethanol (ABS)2 
Dehydration, 
clearing other no no 1 1:00 - - 
6 Xylene1 Xylene1 Dehydration, clearing other no no 1 1:00 - - 
7 Xylene2 Xylene2 Dehydration, clearing other no no 1 1:30 - - 
8 Wax impregnation Wax Wax 
Only 
resistance no 1 2:30 60C - 
 
 
Supplemental Table 5. Leica TP1020 tissue processing protocol for PAXgene-fixed C cores in the 3-core 
study. 
Station Solution Time h:min Temp Vacuum Volume of liquid 
1 PAXgene Stabilizer 0:05 RT off 1 liter 
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2 Ethanol 80% 0:30 RT on 1 liter 
3 Ethanol 90% 1:00 RT on 1 liter 
4 Ethanol 99% 1:00 RT on 1 liter 
5 Ethanol 99% 1:00 RT on 1 liter 
6 Isopropanol 1:00 RT on 1 liter 
7 Isopropanol 1:00 RT on 1 liter 
8 Xylene 1:00 RT on 1 liter 
9 Xylene 1:00 RT on 1 liter 
10 Xylene/ParaplastXtra 50:50 1:00 50°C on 
1 liter (500 ml + 500 
ml) 
11 Paraplast Xtra 1:00 56°C on 1 liter 
12 Paraplast Xtra 1:30 56°C on 1 liter 
 
 
Supplemental Table 6. BioMediTech H&E staining protocol for FFPE B and donor macro sections, and 
PFPE C and D cores in 4-core study. 
Step Reagent Producer, Cat no Time min:sec 
1 Hexane   3:00 
2 Hexane   3:00 
3 ABS EtOH   2:00 
4 ABS EtOH   1:00 
5 94% EtOH   2:00 
6 70% EtOH   1:00 
7 dH2O  MilliQ-distilled H2O 0:30 
8 Hematoxylin Mayers HTX Histolab, Histolab Products AB, Cat No 01820 14:00 
9 H2O   7:00 
10 dH2O MilliQ-distilled H2O 0:40 
11 Eosin  Eosin 0,2% Histolab, Histolab Products AB, Cat No 01650 1:30 
12 H2O   1:00 
13 dH2O MilliQ-distilled H2O 0:30 
14 94% EtOH   2:00 
15 ABS EtOH   2:00 
16 ABS EtOH   2:00 
17 ABS EtOH   2:00 
18 Xylene   2:00 
 
Supplemental Table 7. BioMediTech H&E staining protocol for FF A cores in 4-core study.   
Step Reagent Producer, Cat no Time min:sec 
1 dH2O  MilliQ-distilled H2O 0:30 
14 
 
2 Hematoxylin 
Mayers HTX Histolab, 
Histolab Products AB, Cat No 
01820 
6:00 
3 H2O   7:00 
4 dH2O MilliQ-distilled H2O 0:40 
5 Eosin  Eosin 0,2% Histolab, Histolab Products AB, Cat No 01650 2:00 
6 H2O   1:00 
7 dH2O MilliQ-distilled H2O 0:30 
8 94% EtOH   2:00 
9 94% EtOH   2:00 
10 ABS EtOH   1:00 
11 ABS EtOH   2:00 
12 ABS EtOH   2:00 
13 Xylene   2:00 
 
Supplemental Table 8. Fimlab pathology laboratory H&E staining protocol for FFPE B cores in 3-core study 
 
Step Reagent Producer, Cat no Time min:sec 
1 HistoClear II 1 National diagnostics, HS-202 3:00 
2 HistoClear II 2 National diagnostics, HS-202 3:00 
3 96% EtOH 1 
 
0:10 
4 96% EtOH 2 
 
2:00 
5 70% EtOH 
 
2:00 
6 Running tap water 
 
1:00 
7 Hematoxylin Dako, CS700 0:45 
8 dH20 MilliQ-distilled H2O 1:00 
9 Bluing Buffer Dako, CS702 1:00 
10 Running tap water 
 
1:00 
11 70% EtOH 2 
 
1:00 
12  Eosin Dako, CS701 1:00 
13 96% EtOH 3 
 
1:00 
14 99,9% EtOH 1 
 
1:00 
15 99,9% EtOH 2 
 
1:00 
16 99,9% EtOH 3 
 
1:00 
17 HistoClear II 
 
1:00 
 
 
Supplemental Table 9. BioMediTech H&E staining protocol for PFPE C cores in 3-core study. 
 
Step Reagent Producer, Cat no Time min:sec 
1 HistoClear II 1 National diagnostics, HS-202 3:00 
15 
 
2 HistoClear II 2 National diagnostics, HS-202 3:00 
3 96% EtOH 1 
 
0:10 
4 96% EtOH 2 
 
2:00 
5 70% EtOH 
 
2:00 
6 Running tap water 
 
1:00 
7 Hematoxylin Dako, CS700 0:45 
8 dH20 MilliQ-distilled H2O 1:00 
9 Bluing Buffer Dako, CS702 1:00 
10 Running tap water 
 
1:00 
11 70% EtOH 2 
 
1:00 
12 Eosin diluted 1:2 Dako, CS701 0:05 
13 96% EtOH 3 
 
1:00 
14 99,9% EtOH 1 
 
1:00 
15 99,9% EtOH 2 
 
1:00 
16 99,9% EtOH 3 
 
1:00 
17 HistoClear II 
 
1:00 
 
 
Supplemental Table 10. BioMediTech H&E staining protocol for FF A cores in 3-core study.  
Step Reagent Producer, Cat no Time min:sec 
1 dH2O  MilliQ-distilled H2O 0:30 
2 Hematoxylin 
Mayers HTX Histolab, 
Histolab Products AB, Cat No 
01820 
10:00 
3 H2O   7:00 
4 dH2O MilliQ-distilled H2O 0:40 
5 Eosin diluted 1:2 Eosin 0,2% Histolab, Histolab Products AB, Cat No 01650 0:30 
6 H2O   1:00 
7 dH2O MilliQ-distilled H2O 0:30 
8 94% EtOH   2:00 
9 94% EtOH   2:00 
10 ABS EtOH   1:00 
11 ABS EtOH   2:00 
12 ABS EtOH   2:00 
13 Xylene   2:00 
Supplemental Table 11. DNA MiSeq assay target 
list 
Gene Total size of 
targeted 
region (bp) 
AR 186608 
HES6 755 
TP53 1503 
PTEN 1392 
SMAD4 1879 
MYC 1425 
FOXA1 1459 
KDM5B 5175 
CHD4 6519 
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KMT2C 15916 
CTNNB1 2626 
HOXB13 895 
SPOP 1305 
MED12 7434 
AKT1 1703 
KRAS 787 
EVC 3399 
TMEM33 884 
NPFFR2 1671 
MYOZ2 895 
SPOCK3 1607 
SMPD1 2016 
FSHB 430 
FOLR2 848 
MMP7 924 
CRTAM 1382 
CYFIP1 4743 
EXD1 1745 
LIPC 1680 
ALPK3 6004 
SYNM 4777 
FEM1A 2030 
JUND 1064 
CEBPG 473 
FOSB 1097 
SYT3 1933 
 
 
 
Supplemental Table 12. RNA MiSeq assay Target 
List 
Gene Transcript 
length (bp) 
TBP 2038 
DDX1 2988 
STARD7 3422 
SLC45A3 3702 
HES6 2037 
ACPP 3807 
SKIL 7498 
SPINK1 1478 
FKBP5 10628 
SGK1 6967 
ETV1 8401 
MSMB 1860 
FLI1 4849 
ASCL1 2472 
CHGA 2194 
ETV4 3095 
HPN 2677 
KLK3 2321 
ERG 7498 
TMPRSS2 5418 
SYP 3377 
AR 11810 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 13. Summary of nucleus counts in the 3-core study.  
  FF (A cores) FFPE (B cores) PFPE (C cores) 
Number of nuclei 
per standard slide 
Mean 79839 98609 86892 
SD 15255 19214 19756 
Median 75664 94343 81995 
Estimated number 
of nuclei per 6.2 
mm3 tissue 
Mean 3.08x106 4.01 x106 3.54 x106 
SD 588825 782008 804064 
Median 2.92 x106 3.84 x106 3.34 x106 
 
